TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for All Participants:~* HCV-infected~* Currently on treatment for HCV OR plan to begin treatment for HCV at the start of this study~* Platelet count less than 50,000 cells/microl~* Hemoglobin greater than 10 g/dl OR greater than 11 g/dl if peginterferon treatment-naive~* Red blood cells are Rh (D) antigen-positive~* Negative Coombs direct antibody test~Inclusion Criteria for HIV Infected Group:~* HIV-infected~Inclusion Criteria for HIV Uninfected Group:~* HIV-uninfected~Exclusion Criteria:~* Prior treatment with intravenous immunoglobulin (IVIG), anti-D, or other medication for the treatment of thrombocytopenia within 30 days of study entry~* Prior serious reaction to plasma products~* Absence of spleen~* Evidence of thrombotic thrombocytopenic purpura (TTP) OR cause of thrombocytopenia other than HCV infection, HCV treatment, or HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will be given anti-D in an outpatient setting. Participants will be observed for any adverse effects for 1 hour postinfusion. Some participants may require additional doses of anti-D later in the study, depending on individual response to the drug; participants may receive 1 to 6 doses of anti-D.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavioral Therapy Group for Older Adults Delivered by Telethealth

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* People over the age of 65~* Diagnosis of either or both Major Depressive Disorder (MDD) of mild or moderate severity and an anxiety disorder, including generalized anxiety disorder, social anxiety disorder or panic disorder.~Exclusion Criteria:~* Patients with psychosis~* Patients with dementia~* Patient with severe Major Depressive Disorder or Anxiety Disorder~* Patients with antisocial or borderline personality disorder~* Patients with acute suicidal ideation.~* Older adults who do not have access to the technology required for group; computer, phone or tablet with a webcam and access to Internet~These are also exclusion criteria for the CBT group outside of the study. People younger than 65 are also excluded from the group because it is offered to older adults only.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teletherapy Group CBT participants (Type: EXPERIMENTAL): Patients over the age of 65 with either a Major Depressive Disorder or Generalized Anxiety Disorder who will be participating in a Group CBT delivered by Teletherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented or presumptive HIV infection~* Signs and symptoms of PCP present for at least 5 days~* Pneumocystis jiroveci confirmed in BAL fluid or induced sputum sample~* Suitable candidate for oral therapy~* Alveolar-arterial oxygen (A-a) gradient \< or = 45 mm Hg on room air and partial pressure of oxygen (pO2) \> or = 60 mm Hg~* No more than 48 hours of prior treatment in the preceding 7 days for PCP treatment at full doses; failure of Pneumocystis prophylaxis or use of medications recommended for treatment of PCP at doses less than recommended by the CDC Guidelines is acceptable.~Exclusion Criteria:~* Unwilling or unable to discontinue use of other medications with anti-PCP activity~* AIDS related cachexia (weight loss that is more than 10% of ideal body weight)~* Severe diarrhea and/or vomiting~* History of hypersensitivity or severe or life threatening toxicity to TMP-SMX, other sulfonamides or pentamidine~* Active illicit drug use~* Impending respiratory failure or need for intubation~* AST and ALT levels \> 3 times the upper limit of normal~* History of pancreatitis~* Severe PCP~* Karnofsky score \< or = 20~* Terminal HIV disease or life expectancy of less than 6 months~* Acute concurrent pulmonary pathological condition that would obscure the evaluation of response to therapy~* Concomitant use of amphotericin B, gangciclovir, cyclosporine, warfarin, thiazide diuretics, phenytoin, methotrexate, leucovorin~* Receipt of systemic corticosteroids (except replacement therapy) within 14 days of study entry at high doses for 3 or more consecutive days. Concomitant use of corticosteroids, other than replacement doses for adrenal insufficiency, is also excluded unless the patient meets the CDC criteria for use of corticosteroids for treatment of PCP~* Pregnant or lactating women~* The subject has been previously enrolled in the study

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): pafuramidine maleate, oral tablet, 100 mg bid X 14 days
- 2 (Type: ACTIVE_COMPARATOR): TMP/SMX oral tablet, 15 mg/kg, split tid X 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a documented clinical diagnosis of grade II-IV acute graft-versus- host disease defined as graft versus host disease (GVHD) occurring within the first 100 days of transplantation~* Patients must be steroid-refractory defines as progression after 3 days of corticosteroid therapy or no response after 5 days of corticosteroid therapy.~* Progression is defined as up-grading~* No response is defined as no down-grading~* Progression after 3 days requires patients to have received at least 2 mg/mg/day for a total of 6 mg/kg of methylprednisolone or its equivalent.~* No response after 5 days requires patient to have received at least 2 mg/kg/d for a total of 10 mg/kg of methylprednisolone or its equivalent.~* Patients with exacerbation of GVHD during steroid taper will require re-treatment with 2mg/kg/d of corticosteroids and will need to meet the criteria~* Age 18-70~* Patients must have received an allogeneic hematopoietic stem cell transplant within 100 days of study enrollment.~* Serum creatinine \< 2 mg/dL~Exclusion Criteria:~* Patients cannot have active central nervous system (CNS) disease.~* Patients must not have received cyclophosphamide for GVHD prophylaxis~* Patients must not have pneumonia requiring oxygen supplementation~* Unable or unwilling to sign informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide and Sirolimus (Type: EXPERIMENTAL): cyclophosphamide and sirolimus combo
- Lowdose IL-2, Cytoxan + Sirolimus (Type: EXPERIMENTAL): Low dose IL-2 with Cytoxan + Sirolimus Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.
- Lowdose IL-2, Vidaza, cyclophosphamide & Sirolimus (Type: EXPERIMENTAL): Lowdose IL-2, Vidaza, cyclophosphamide (Cytoxan) \& Sirolimus Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Hip Fracture and Patent Foramen Ovale

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* hip fracture requiring a surgical procedure~Exclusion Criteria:~* simultaneous other traumatic lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- detection of a patent foramen ovale (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Esophageal and Anorectal Manometry Catheters

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18-80 years old~* Ability to give informed consent~* No significant medical conditions~* Abnormal esophageal motility~* Abnormal anorectal motility~Exclusion Criteria:~* Previous esophageal or anorectal surgery, anatomic abnormalities or dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Solid state catheter
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cocoa Consumption in Cardiovascular and Immune Parameters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 - 65 years old~* Resides in Medellín City~* Attached from the contributive regimen of Colombian Health System~* Essential Arterial Hypertension, stage I. Diagnosis less than 3 months.~* Medically indicated non-pharmacological therapy.~* Voluntary desire to consume 50 grams of chocolate per day for 12 weeks.~* Voluntary desire to participate in the trial and sign informed consent.~Exclusion Criteria:~* Suspect of secondary hypertension~* Suspect of injury in target organ~* Presence of diabetes mellitus~* BMI (Body Mass Index) major or equal to 30~* Present smoker or with less than four weeks of abstinence of tobacco~* Consume antiplatelet substances~* Regular consumption of antioxidants, multivitamins, anti-inflammatory medications, drugs for nasal congestion and sibutramine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dark chocolate (Type: ACTIVE_COMPARATOR): Presence of 70% cocoa solids
- White chocolate (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* B-cell chronic lymphocytic leukemia (a) Rai stage 0-II with indication for treatment by NCI Working Group Criteria: or (b) Rai stage III or IV.~* Received a minimum of one prior chemotherapy regimen. Prior treatment with corticosteroids, immunotherapies, monoclonal antibodies or radiation therapy is permitted.~* White blood cell count \> 25 x 10\^9/L~* ECOG 0, 1,or 2.~* Adequate renal and hepatic function~* Platelets \> 75 x 10\^9/L, transfusion independent.~* Neutrophils \> 1.0 x 10\^9/L, transfusion independent~Exclusion Criteria:~* Documented prolymphocytic leukemia (PLL; prolymphocytes, 55% in blood)~* Active cardiovascular disease as defined by NYHA class III-IV categorization.~* Intercurrent illness or medical condition precluding safe administration of ribavirin.~* Concurrent use of chronic steroids, except as replacement therapy for adrenal insufficiency~* Known infection with HIV, Hepatitis B or C.~* Concurrent malignancy (other than resected basal or squamous cell skin cancers or in-situ carcinoma).~* Received any previous therapy for CLL within 28 days prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Gleevec Chlorambucil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Digital Photography to Estimate Anthropometric Measurements in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children age 2-18 years old.~* Seen on Mayo 16 for an outpatient clinic appointment.~Exclusion Criteria:~* Participant unable to stand for stadiometer height~* Pregnant patients

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Photography to Measure Children's Height, Wrist Circumference, and Abdominal Circumference (Type: EXPERIMENTAL): Subjects will be given instructions on how to take two photographs at home and submit them securely. Subjects will also be given instructions on how to measure height, wrist circumference, and waist circumference and submit this data to the research team.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: FENO, Extended NO Analysis and NO/CO Diffusing Capacity in Thoracic Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* planned but not already commenced radiation therapy (RT) of the chest, with or without pre-RT surgery.~* signed informed consent of the participant~Exclusion Criteria:~* thoracic RT in the past~* treatment with immune checkpoint inhibitors~* unstable condition affecting participation in the measurements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Lung Volume Reduction Coil Treatment in Patients With Chronic Hypercapnic Respiratory Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with emphysema (chronic obstructive pulmonary disease with forced expired volume in one second (FEV1) \< 50% predicted and residual volume (RV) ≥ 200% predicted) in whom endoscopic lung volume reduction coil treatment is performed~* Chronic hypercapnic respiratory failure (PaCO2 ≥ 50 mmHg)~* Informed consent~Exclusion Criteria:~* Therapeutic anticoagulation~* Anti-platelet therapy exceeding the use of acetylsalicylic acid~* Severe pulmonary hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Concussion Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~In order to be eligible to participate in this study, an individual must meet all of the following criteria:~1. Provision of signed and dated informed consent form~2. Stated willingness to comply with all study procedures and availability for the duration of the study~3. Participants aged 13-21 years old~4. In good general health as evidenced by medical history and diagnosed with recent head trauma meeting ICHD-3 criteria for acute posttraumatic headache with symptom onset \< 7 days from trauma~5. Ability to take oral medication and be willing to adhere to the medication regimen~6. No loss of consciousness OR loss of consciousness \<30 minutes~7. Headache symptoms persisting ≥4 weeks post trauma~8. PCSHE score for headache + pressure in head + neck pain must be \> 3~9. After week 4 post-concussion at time of enrollment~10. Not currently receiving pharmacologic treatment for concussion asid from NSAIDs and acetaminophen~Exclusion Criteria:~An individual who meets any of the following criteria will be excluded from participation in this study:~1. Focal neurological deficits following injury~2. Any acute abnormality on Computed Tomography (if obtained)~3. History of known seizure disorder or moderate or severe TBI~4. Current uncontrolled psychiatric illness given the potential side effects of the study drug (at investigator discretion).~5. Current suicidal ideation as screened for on PHQ on intake~6. A personal history of Brugada syndrome~7. Known allergic reaction to nortriptyline~8. Current pregnancy~9. Positive COVID-19 test in prior 14 days

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 21 Years
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: EXPERIMENTAL): 10mg capsule once daily for 4 weeks of nortriptyline
- Control (Type: PLACEBO_COMPARATOR): 10mg capsule once daily for 4 weeks of Thick-It filler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Anesthesia on Mechanical Efficiency of Left Ventricle in Patients Undergoing Open Heart Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing elective cardiac surgery~Exclusion Criteria:~* Emergent surgery.~* History of previous cardiac surgery.~* Significant arrhythmias.~* More than trivial valvular disorder.~* Absence of written informed consent.~* Contraindications for transesophageal echocardiography.~* Pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhalational anesthesia (Type: ACTIVE_COMPARATOR): Group of patients undergoing the surgery under anesthesia based on inhalational anesthetic
- TIVA (Type: ACTIVE_COMPARATOR): Group of patients undergoing the surgery under total intravenous anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: INBONE Total Ankle Arthroplasty(TAA)Using Calcaneal Stem Fixation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients who will be recruited for participation in this study received the TAA with calcaneal stem between December 6, 2005 and November 13, 2007 at approximately 28 sites.~Exclusion Criteria:~Patients who will be recruited for participation in this study received the TAA with calcaneal stem between December 6, 2005 and November 13, 2007 at approximately 28 sites.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Total Ankle Arthroplasty with calcaneal stem (Type: None): Patients received the TAA with calcaneal stem between 12/6/05 \& 11/13/07 at approximately 28 sites.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Tolerance of Cereals for Atopic Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infant aged from 4 to 40 months at the time of enrolment~* With atopic symptoms and/or positive Skin Prick Test (SPT) or positive specific RAST-IgE or positive Patch Test~* Infants who received a specific elimination oligoallergenic diet from the study site for at least 5 days before the day of enrolment~* Having obtained his/her signed legal representative's informed consent~Exclusion Criteria:~* Infant on systemic drugs (e.g. antihistamines) according to half-life at time of enrolment~* Congenital illness or malformation that may affect normal growth (especially immunodeficiency)~* Infant whose parents / caregivers cannot be expected to comply with treatment.~* Infant currently participating in another interventional clinical trial

- Gender: ALL
- Minimum Age: 4 Months
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- complete non allergenic cereals (Type: ACTIVE_COMPARATOR): existing commercialized product
- complete non allergenic cereals plus (Type: EXPERIMENTAL): commercialised product with the addition of a novel ingredient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility